New York, November 4, 2004 – Combination therapy with Pfizer Inc's DETROL® LA (tolterodine tartrate extended release capsules) and an alpha blocker, a standard treatment for enlarged prostate, was ...
NEW YORK (AP) -- Mylan Inc. plans to start selling a generic version of Pfizer Inc.'s overactive bladder drug Detrol LA in early 2014, as the two drugmakers said Friday they have resolved lawsuits ...
New York, December 13, 2004 – Pfizer Inc today announced results of a comprehensive six-year review of efficacy and safety data for DETROL® LA (tolterodine tartrate extended release capsules) ...
Detrol, or Tolterodine Tartrate IR tablets, are indicated for the treatment of overactive bladder. Inactive ingredients found in the medication include colloidal silicon dioxide, dibasic calcium ...
(Reuters) - Pfizer Inc has settled a lawsuit accusing Impax Laboratories Inc of infringing patents covering the overactive bladder drug Detrol LA. The settlement was disclosed in court papers filed in ...
Pfizer and Impax Laboratories have reached an undisclosed accommodation on if and when Impax will be able to launch a generic of Pfizer's bladder-control drug Detrol LA. Detrol and the ...
Global pharmaceutical company Pfizer has announced that it has settled its litigation against Mylan Pharmaceuticals relating to Pfizer’s patents covering Detrol LA (tolterodine tartrate) ...
Pfizer Inc. (NYSE: PFE) announced today that a Phase 4 study assessing the efficacy and safety of Toviaz(fesoterodine fumarate) in patients with overactive bladder (OAB) met its primary endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results